-
srdr.ahrq.gov/projects/1165
May 29, 2019 - (DD)—major depressive disorder (MDD), persistent depressive disorder (PDD, previously termed dysthymia … How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics … How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics … How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics … Belmaker
2006
Paroxetine treatment in children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186915
January 01, 2006 - international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186944
January 01, 2018 - Description
Predictors and moderators of relapse in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Title
Predictors and moderators of relapse in children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186913
January 01, 2006 - Title and Description
Paroxetine treatment in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Title Data
Title
Paroxetine treatment in children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186939
January 01, 1992 - double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186945
January 01, 2018 - Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186943
January 01, 2018 - double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186954
January 01, 2018 - Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186893
January 01, 2014 - efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186894
January 01, 2014 - efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1165/studies/186941
January 01, 2009 - Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder
-
srdr.ahrq.gov/projects/1324/studies/192174
January 01, 2019 - Title and Description
Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder … Title Data
Title
Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder … Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: Groundwork for a Publicly
-
srdr.ahrq.gov/projects/1626/studies/193192
January 01, 2003 - Preview
Study Title and Description
Health care costs associated with posttraumatic stress disorder … Title Data
Title
Health care costs associated with posttraumatic stress disorder
-
srdr.ahrq.gov/projects/1596/studies/192276
January 01, 2017 - naloxone reduce morbidity or mortality, or improve other health outcomes in persons with opioid use disorder … What are the harms of naloxone in persons with opioid use disorder or misuse?
-
srdr.ahrq.gov/projects/1596/studies/192277
January 01, 2016 - naloxone reduce morbidity or mortality, or improve other health outcomes in persons with opioid use disorder … What are the harms of naloxone in persons with opioid use disorder or misuse?
-
srdr.ahrq.gov/projects/1596/studies/192268
January 01, 2001 - Description
A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder … A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder
-
srdr.ahrq.gov/projects/1596/studies/192269
January 01, 2001 - Description
Clinical profile of participants in a brief intervention program for cannabis use disorder … Title
Clinical profile of participants in a brief intervention program for cannabis use disorder
-
srdr.ahrq.gov/projects/1165/studies/186921
January 01, 2004 - study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder … study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder
-
srdr.ahrq.gov/projects/1165/studies/186948
January 01, 2012 - and bupropion for the treatment of problematic on-line game play in adolescents with major depressive disorder … and bupropion for the treatment of problematic on-line game play in adolescents with major depressive disorder
-
srdr.ahrq.gov/projects/1671/studies/196089
January 01, 1995 - nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1) misuse, opioid use disorder … acute treatment, what is the accuracy of instruments for predicting risk of opioid misuse, opioid use disorder … treatment, what is the effectiveness of instruments for predicting risk of opioid misuse, opioid use disorder